Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Indegene Limited (INDGN.NS)
Bengaluru, IN
Operating globally with a strong presence in India, Indegene Limited functions as a specialized commercialization partner for the life sciences industry. It provides comprehensive support to biopharmaceutical, emerging biotech, and medical device companies, assisting them from product development and market access to maximizing their impact throughout the product lifecycle. The company's service offerings include enterprise commercial, medical, and clinical solutions, coupled with omnichannel activation strategies and proprietary NEXT technology platforms. Indegene was established in 1998 and its principal operations are based in Bengaluru, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.71% | -0.96% | -2.79% | +8.02% | -2.30% | -0.38% | -14.36% | -9.19% | -9.19% | -9.19% | -9.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+23.6% ★ Q1'26: +32.8% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-2.4% Q1'26: -32.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+16.5% Q1'26: +18.6% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+14.0% ★ Q1'26: +12.1% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+20.9% ★ Q1'26: +20.5% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+1.0% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.23× ★ Q1'26: 0.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 5 EPS Ana. |
Mar 2027 7 Rev. Ana. 7 EPS Ana. |
Mar 2028 7 Rev. Ana. 6 EPS Ana. |
Mar 2029 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
25.90B
est: 26.59B (-2.6%)
|
28.39B
est: 28.47B (-0.3%)
|
35.28B
34.57B – 36.88B
+23.9% YoY
|
43.06B
40.40B – 44.38B
+22.1% YoY
|
48.31B
44.31B – 51.67B
+12.2% YoY
|
55.31B
55.31B – 55.31B
+14.5% YoY
|
| EBITDA |
5.81B
est: 5.53B (+5.0%)
|
6.42B
est: 5.92B (+8.3%)
|
7.34B
7.19B – 7.67B
+23.9% YoY
|
8.96B
8.41B – 9.23B
+22.1% YoY
|
10.05B
9.22B – 10.75B
+12.2% YoY
|
11.51B
11.51B – 11.51B
+14.5% YoY
|
| EBIT |
5.05B
est: 4.14B (+22.0%)
|
5.61B
est: 4.43B (+26.6%)
|
5.49B
5.38B – 5.74B
+23.9% YoY
|
6.70B
6.29B – 6.91B
+22.1% YoY
|
7.52B
6.90B – 8.04B
+12.2% YoY
|
8.61B
8.61B – 8.61B
+14.5% YoY
|
| Net Income |
3.37B
est: 3.56B (-5.4%)
|
4.07B
est: 3.99B (+1.8%)
|
4.42B
4.32B – 4.53B
+10.7% YoY
|
5.11B
4.86B – 5.66B
+15.6% YoY
|
6.38B
5.99B – 6.86B
+24.8% YoY
|
7.48B
6.96B – 7.92B
+17.3% YoY
|
| SGA |
16.56B
est: 13.46B (+23.0%)
|
18.20B
est: 14.41B (+26.3%)
|
17.86B
17.50B – 18.67B
+23.9% YoY
|
21.80B
20.46B – 22.47B
+22.1% YoY
|
24.46B
22.43B – 26.16B
+12.2% YoY
|
28.00B
28.00B – 28.00B
+14.5% YoY
|
| EPS |
14.09
est: 15.88 (-11.3%)
|
17.15
est: 16.79 (+2.2%)
|
18.25
17.88 – 18.76
+8.7% YoY
|
21.97
20.13 – 23.46
+20.4% YoY
|
27.23
24.83 – 28.40
+24.0% YoY
|
31.04
28.83 – 32.83
+14.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-06-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Manish Gupta | Executive Chairman & Chief Executive Officer | 37M | male |
| Sanjay Suresh Parikh | Executive Director & Executive Vice President | 25M | — |
| Bina Patil | Vice President and Human Resources & Grievance Officer | — | female |
| Karthik Kannappan Saravanan | Vice President of Legal & Group General Counsel | — | male |
| Shouvanik Chatterjee | Senior Vice President of Corporate Development | — | male |
| Srishti Ramesh Kaushik | Company Secretary & Compliance Officer | — | female |
| Suhas Prabhu | Chief Financial Officer | — | male |
| Abhishek Agarwal | Head of Investor Relations | — | — |
| Tarun Mathur | Chief Technology Officer | — | male |
| Anand Kiran Prafula Chandra Nijegal | Executive Vice President of Global Operations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INDGN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
